By employing CRISPR/Cas9 to knock down BIG1 and BIG2 and subsequently reduce VEGF levels, the study aimed to disrupt the angiogenic signals that contribute to the vascularization of GBM tumors. This evidence concerns the gene VEGFA and glioblastoma.